Cannabidiol for the treatment of patients with West syndrome and epilepsy
DOI:
https://doi.org/10.33448/rsd-v9i9.7267Keywords:
Therapeutic alternative; Cannabis sativa; Infantile spasms; Marijuana; Medicinal use.Abstract
Cannabinoid compounds have therapeutic properties, but also psychotropic effects. Cannabidiol (CBD) extracted from Cannabis sativa has been used in cases of epilepsy, a disorder that occurs in the brain caused by genetic predisposition, as in West Syndrome. Epilepsies and their symptoms can cause neurobiological, cognitive and psychosocial consequences, especially when not treated in a timely manner and accompanied by a qualified professional. Given the above, the present study aims to conduct an integrative review, reporting a clinical case of a patient with West Syndrome, to assess the benefits of using cannabidiol in treatment of epilepsy. An integrative review was conducted based on research in electronic databases, and the clinical case was described. The administration of CBD had beneficial effects in the adjunctive treatment to other antiepileptics. The patient was treated with CBD for 7 months and improvements in interaction were found, she had greater perception and smarter interaction with the world around her. It is essential that a trained professional who understands the subject accompanies the patient in each progression or regression of the dose for crisis control. There is still a lot to study about the use of CBD in the treatment of epilepsy, and also about West Syndrome, because the effects of CBD depend a lot on the organism and the type of crisis of each patient.
References
Barbosa, M. G. A., Barros, É. F. A., Lima, G. R., Silva, G. F. & Souza, P. G. V. D. (2020). O uso do composto de Canabidiol no tratamento da doença de Alzheimer (revisão da literatura). Research, Society and Development, 9(8), e442986073. doi:http://dx.doi.org/10.33448/rsd-v9i8.6073
Basilio, P. V. & Ferreira, R. C. V. (2019). A importância do uso do canabidiol em pacientes com epilepsia. Revista Saúde UniToledo, Araçatuba, 3(2), 86-96. Disponível em: http://www.ojs.toledo.br/index.php/saude/article/view/3435/566. Acesso em: 24 junho 2020.
Brasil. (2020). Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Diretoria Colegiada. Resolução - RDC nº 335, de 24 de janeiro de 2020. Define os critérios e os procedimentos para a importação de Produto derivado de Cannabis, por pessoa física, para uso próprio, mediante prescrição de profissional legalmente habilitado, para tratamento de saúde. Diário Oficial da União. Publicado em: 27/01/2020, Edição: 18, Seção: 1, Página: 54.
Calderón Romero, M., Arce Portillo, E., López Lobato, M., Muñoz Cabello, B., Blanco Martínez, B., Madruga Garrido, M. & Alonso Luego, O. (2018). Síndrome de West criptogénico: perfil clínico, respuesta al tratamiento y factores pronósticos [Cryptogenic West syndrome: Clinical profile, response to treatment and prognostic factors]. Anales de Pediatria (Barcelona, Spain: 2003), 89(3), 176–182. https://doi.org/10.1016/j.anpedi.2017.10.012
Çetin, Ö. E., Yalçınkaya, C., Karaman, B., Demirbilek, V. & Tüysüz, B. (2018). Chromosome 14q11.2-q21.1 duplication: a rare cause of West syndrome. Epileptic Disorders: International Epilepsy Journal With Videotape, 20(3), 219–224. https://doi.org/10.1684/epd.2018.0972
Crippa, J. A., Guimarães, F. S., Campos, A. C. & Zuardi, A. W. (2018). Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Frontiers In Immunology, 9, 2009. https://doi.org/10.3389/fimmu.2018.02009
Crippa, J. A., Zuardi, A. W. & Hallak, J. E. (2010). Uso terapêutico dos canabinoides em psiquiatria [Therapeutical use of the cannabinoids in psychiatry]. Revista Brasileira de Psiquiatria (Sao Paulo, Brazil: 1999), 32(Suppl 1), S56–S66. doi:http://dx.doi.org/10.1590/S1516-44462010000500009.
Crippa, J., Hallak, J., Zuardi, A. W., Guimarães, F. S., Tumas, V. & Dos Santos, R. G. (2019). Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 121–133. https://doi.org/10.1007/s00406-019-00982-6
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., Wong, M., Tilton, N., Bruno, P., Bluvstein, J., Hedlund, J., Kamens, R., Maclean, J., Nangia, S., Singhal, N. S., Wilson, C. A., … & Cilio, M. R. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet. Neurology, 15(3), 270–278. doi:https://doi.org/10.1016/S1474-4422(15)00379-8.
Gaston, T. E. & Szaflarski, J. P. (2018). Cannabis for the Treatment of Epilepsy: an Update. Current Neurology and Neuroscience Reports, 18(11), 73. https://doi.org/10.1007/s11910-018-0882-y
Henriques-Souza, A. M., Ataide Junior, L. & Laurentino, S. G. (2007). Vigabatrina no tratamento da síndrome de West. Avaliação clínica e eletrencefalográfica em 13 pacientes [Treatment of West syndrome with vigabatrin: clinical and electroencephalographic evaluation of 13 patients]. Arquivos de Neuro-Psiquiatria, 65(1), 144–149. https://doi.org/10.1590/s0004-282x2007000100029
Hussain, S. A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., Hung, P., Lerner, J. T. & Sankar, R. (2015). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy & Behavior: E&B, 47, 138–141. https://doi.org/10.1016/j.yebeh.2015.04.009
Lata H., Chandra S., Khan I.A. & ElSohly M.A. (2017). Micropropagation of Cannabis sativa L.—An Update. In: Chandra S., Lata H., ElSohly M. (eds) Cannabis sativa L. - Botany and Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-319-54564-6_13
Matos, R. L. A., Spinola, L. A., Barboza, L. L., Garcia, D. R., França, T. C. C. & Affonso, R. S. (2017). O uso do canabidiol no tratamento da epilepsia. Revista Virtual de Química, 9(2), 786-814. doi:10.21577/1984-6835.20170049
McPartland, J. M. & Small, E. (2020). A classification of endangered high-THC cannabis (Cannabis sativa subsp. indica) domesticates and their wild relatives. PhytoKeys, 144, 81-112. https://doi.org/10.3897/phytokeys.144.46700
Osborne, J. P., Edwards, S. W., Dietrich Alber, F., Hancock, E., Johnson, A. L., Kennedy, C. R., Likeman, M., Lux, A. L., Mackay, M., Mallick, A., Newton, R. W., Nolan, M., Pressler, R., Rating, D., Schmitt, B., Verity, C. M., O'Callaghan, F., & participating investigators (2019). The underlying etiology of infantile spasms (West syndrome): Information from the International Collaborative Infantile Spasms Study (ICISS). Epilepsia, 60(9), 1861–1869. https://doi.org/10.1111/epi.16305
Pavone, P., Striano, P., Falsaperla, R., Pavone, L., & Ruggieri, M. (2014). Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013. Brain & Development, 36(9), 739–751. https://doi.org/10.1016/j.braindev.2013.10.008
Pereira A. S., et al. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. Disponível em: https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1.
Peruzzo, B. G., Tormem, L. T. & Souza, P. A. (2020). Epidemiologia das Doenças Neurológicas não Infectocontagiosas na infância em um Hospital na Serra Catarinense em 2014. Research, Society and Development, 9(7), e876975012. http://dx.doi.org/10.33448/rsd-v9i7.5012
Porto, C. C. Semiologia médica. In: Celmo Celeno Porto; co-editor Arnaldo Lemos Porto. 7. ed. Rio de Janeiro: Guanabara Koogan, 2014.
Reithmeier, D., Tang-Wai, R., Seifert, B., Lyon, A. W., Alcorn, J., Acton, B., Corley, S., Prosser-Loose, E., Mousseau, D. D., Lim, H. J., Tellez-Zenteno, J., Huh, L., Leung, E., Carmant, L. & Huntsman, R. J. (2018). The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study. BMC Pediatrics, 18(1), 221. https://doi.org/10.1186/s12887-018-1191-y
Song, J. M., Hahn, J., Kim, S. H. & Chang, M. J. (2017). Efficacy of Treatments for Infantile Spasms: A Systematic Review. Clinical Neuropharmacology, 40(2), 63–84. https://doi.org/10.1097/WNF.0000000000000200
Sulak, D., Saneto, R. & Goldstein, B. (2017). The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy & Behavior: E&B, 70(Pt B), 328–333. https://doi.org/10.1016/j.yebeh.2016.12.032
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Thaís Ribeiro Garcia; Miguel Carlos Azevedo Cruz; Geovanna de Oliveira Araújo Silva; Eduardo Francisco Cardoso; Jalsi Tacon Arruda
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
